BACKGROUND: New pharmacotherapies to treat alcohol use disorders (AUD) are needed. Given the complex nature of AUD, there likely exist multiple novel drug targets. We, and others, have shown that the tetracycline drugs, minocycline and doxycycline, reduced ethanol (EtOH) drinking in mice. To test the hypothesis that suppression of high EtOH consumption is a general property of tetracyclines, we screened several derivatives for antidrinking activity using the Drinking-In-the-Dark (DID) paradigm. Active drugs were studied further using the dose-response relationship. METHODS: Adult female and male C57BL/6J mice were singly housed and the DID paradigm was performed using 20% EtOH over a 4-day period. Mice were administered a tetracycline or its vehicle 20 hours prior to drinking. Water and EtOH consumption was measured daily. Body weight was measured at the start of drug injections and after the final day of the experiment. Blood was collected for EtOH content measurement immediately following the final bout of drinking. RESULTS: Seven tetracyclines were tested at a 50 mg/kg dose. Only minocycline and tigecycline significantly reduced EtOH drinking, and doxycycline showed a strong effect size trend toward reduced drinking. Subsequent studies with these 3 drugs revealed a dose-dependent decrease in EtOH consumption for both female and male mice, with sex differences in efficacy. Minocycline and doxycycline reduced water intake at higher doses, although to a lesser degree than their effects on EtOH drinking. Tigecycline did not negatively affect water intake. The rank order of potency for reduction in EtOH consumption was minocycline > doxycycline > tigecycline, indicating efficacy was not strictly related to their partition coefficients or distribution constants. CONCLUSIONS: Due to its effectiveness in reducing high EtOH consumption coupled without an effect on water intake, tigecycline was found to be the most promising lead tetracycline compound for further study toward the development of a new pharmacotherapy for the treatment of AUD.
BACKGROUND: New pharmacotherapies to treat alcohol use disorders (AUD) are needed. Given the complex nature of AUD, there likely exist multiple novel drug targets. We, and others, have shown that the tetracycline drugs, minocycline and doxycycline, reduced ethanol (EtOH) drinking in mice. To test the hypothesis that suppression of high EtOH consumption is a general property of tetracyclines, we screened several derivatives for antidrinking activity using the Drinking-In-the-Dark (DID) paradigm. Active drugs were studied further using the dose-response relationship. METHODS: Adult female and male C57BL/6J mice were singly housed and the DID paradigm was performed using 20% EtOH over a 4-day period. Mice were administered a tetracycline or its vehicle 20 hours prior to drinking. Water and EtOH consumption was measured daily. Body weight was measured at the start of drug injections and after the final day of the experiment. Blood was collected for EtOH content measurement immediately following the final bout of drinking. RESULTS: Seven tetracyclines were tested at a 50 mg/kg dose. Only minocycline and tigecycline significantly reduced EtOH drinking, and doxycycline showed a strong effect size trend toward reduced drinking. Subsequent studies with these 3 drugs revealed a dose-dependent decrease in EtOH consumption for both female and male mice, with sex differences in efficacy. Minocycline and doxycycline reduced water intake at higher doses, although to a lesser degree than their effects on EtOH drinking. Tigecycline did not negatively affect water intake. The rank order of potency for reduction in EtOH consumption was minocycline > doxycycline > tigecycline, indicating efficacy was not strictly related to their partition coefficients or distribution constants. CONCLUSIONS: Due to its effectiveness in reducing high EtOH consumption coupled without an effect on water intake, tigecycline was found to be the most promising lead tetracycline compound for further study toward the development of a new pharmacotherapy for the treatment of AUD.
Authors: S Alex Marshall; John D Casachahua; Jennifer A Rinker; Allyson K Blose; Donald T Lysle; Todd E Thiele Journal: Brain Behav Immun Date: 2015-09-10 Impact factor: 7.217
Authors: Paul D Drew; Jennifer W Johnson; James C Douglas; Kevin D Phelan; Cynthia J M Kane Journal: Alcohol Clin Exp Res Date: 2015-02-19 Impact factor: 3.455
Authors: Yuri A Blednov; Susan E Bergeson; Danielle Walker; Vania M M Ferreira; William A Kuziel; R Adron Harris Journal: Behav Brain Res Date: 2005-08-18 Impact factor: 3.332
Authors: Susan E Bergeson; Michelle A Nipper; Jeremiah Jensen; Melinda L Helms; Deborah A Finn Journal: Alcohol Clin Exp Res Date: 2016-11-14 Impact factor: 3.455
Authors: Joseph M Martinez; Jessica A Groot; David C Curtis; Clayton L Allison; Patrick C Marquardt; Ashley N Holmes; David S Edwards; David R M Trotter; Peter J Syapin; Deborah A Finn; Susan E Bergeson Journal: Alcohol Clin Exp Res Date: 2016-11-14 Impact factor: 3.455
Authors: John C Crabbe; Angela R Ozburn; Robert J Hitzemann; Stephanie E Spence; Wyatt R Hack; Jason P Schlumbohm; Pamela Metten Journal: Brain Behav Immun Health Date: 2020-03-19
Authors: Ryan K Bachtell; Jermaine D Jones; Keith G Heinzerling; Patrick M Beardsley; Sandra D Comer Journal: Drug Alcohol Depend Date: 2017-08-31 Impact factor: 4.492
Authors: Susan E Bergeson; Henry Blanton; Joseph M Martinez; David C Curtis; Caitlyn Sherfey; Brandon Seegmiller; Patrick C Marquardt; Jessica A Groot; Clayton L Allison; Christian Bezboruah; Josée Guindon Journal: Alcohol Clin Exp Res Date: 2016-11-14 Impact factor: 3.455
Authors: Maria Carolina Machado da Silva; Giovanni Freitas Gomes; Heliana de Barros Fernandes; Aristóbolo Mendes da Silva; Antônio Lúcio Teixeira; Fabrício A Moreira; Aline Silva de Miranda; Antônio Carlos Pinheiro de Oliveira Journal: Sci Rep Date: 2021-08-06 Impact factor: 4.379